Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Regulatory and Compliance Updates news
(page 13)
23 March 2026
Ercros: EcoVadis Gold, 85/100
Ranks in the 98th percentile; environment & ethics 91, labour & human rights 90. Advanced management, many KPIs provided; 100/100 for endorsements, measures and certifications
23 March 2026
BASF converts Ludwigshafen acid chlorides and chloroformates to 100% renewable electricity credits
Average product carbon footprint cut ~19% in 2025; plant modernization raised capacity ~30%; customers get lower‑PCF supplies without recertification, aiding Scope 3 reductions.
23 March 2026
Chugai obtains MHLW approval for Lunsumio–Polivy combo in relapsed/refractory large B‑cell lymphoma
Japan approves Lunsumio + Polivy for relapsed/refractory large B‑cell lymphoma after Phase III SUNMO: ORR 69.7%, PFS 11.5 vs 3.8 months (59% lower progression/death risk); manageable safety.
23 March 2026
GSK’s risvutatug rezetecan granted orphan drug designation for SCLC in Japan
Risvutatug rezetecan, a B7-H3–targeted ADC, showed durable responses in extensive‑stage SCLC in phase I ARTEMIS‑001; global phase III in relapsed ES‑SCLC is underway.
20 March 2026
Petrobras resumes investments in Minas Gerais during Lula visit
During Lula’s visit to Regap (Betim), resumption of investments announced: R$3.8bn (2026–30), up to R$9bn/10 yrs; 8k–36k jobs; +25k bpd capacity (2027) and 13.3 MW solar plant.
19 March 2026
FDA approves Novo Nordisk’s Wegovy HD (7.2 mg) after ~21% weight loss in STEP UP trial
Higher‑dose semaglutide injection approved for adults with obesity after tolerating 2.4 mg; 31% reached ≥25% weight loss. Common AEs: GI symptoms and dysesthesia/altered skin sensation. Available April.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
19 March 2026
Novo Nordisk: FDA approves Wegovy HD (semaglutide 7.2 mg) — 20.7% mean weight loss
STEP UP: ~31% achieved ≥25% loss; STEP UP T2D mean loss 14.1%. FDA awarded National Priority Voucher. US launch expected April 2026. Safety/tolerability comparable to prior semaglutide doses.
19 March 2026
GSK: Lynavoy (linerixibat) FDA-approved for cholestatic pruritus in PBC
FDA approved linerixibat for cholestatic pruritus in adults with PBC after GLISTEN phase III showed rapid, sustained itch and sleep improvements. Common AEs: diarrhea, abdominal pain.
19 March 2026
Clariant opens pharma-grade PEG manufacturing plant in Texas
GMP-compliant excipient production strengthens supply-chain resilience, shortens lead times, and improves continuity and traceability for pharma customers across North & Latin America.
19 March 2026
Equinor Annual Report 2025
Record production and strong cash results in 2025; safety improved; adjusted operating income $27.6B; production 2,137 mboe/d; renewables +25%; emissions −34% since 2015.
18 March 2026
Petrobras Contracts 8 Thermoelectric Plants in 2026 Capacity Reserve Auction
Result secures ~R$4bn annual fixed revenue, requires signing CRCAPs, proving firm fuel supply and meeting ONS operational rules; portfolio totals 4.9 GW, supporting SIN availability
18 March 2026
Eni 2025 Financial Statements
Board approved 2025 Annual Report: consolidated net profit €2,608m, parent €4,429m. 4th dividend scheduled (ex-div May 18, pay May 20). AGM May 6; governance, sustainability and remuneration reports to be published.
18 March 2026
Johnson & Johnson FDA approves ICOTYDE (icotrokinra) for first‑line systemic treatment of plaque psoriasis
First targeted oral IL‑23 receptor peptide approved for moderate‑to‑severe plaque psoriasis in adults and ≥12 (≥40kg). Once‑daily pill; ~70% IGA0/1, 55% PASI90 at Week16; safety like placebo.
18 March 2026
Boliden invests SEK 4bn in Garpenberg hoist and SEK 1.5bn in Rönnskär SCM plant
SEK 4bn hoist at Garpenberg to keep 4.5 Mt/yr past 2030; SEK 1.5bn Rönnskär demo plant (280 kt/yr SCMentum) 2026–28. SCM emits <5% of cement CO2; exploration continues.
18 March 2026
Avantium reports 2025 full-year results
Phased start-up of the FDCA Flagship Plant progressed despite construction delays; €85M equity and amended financing secured; half the plant operational; full start-up targeted in 2026
17 March 2026
Perimeter Solutions: SOLBERG EVOLUTION 3% SFFF — first Newtonian fluorine‑free foam with FM approval
Mil‑Spec and ICAO Level B certified; UL‑162 approved for fixed sprinkler use; compatible with standard sprinkler hardware and aircraft surfaces; PFAS‑free, biodegradable; validated for ARFF
17 March 2026
Vioneo on the EU Single‑Use Plastics Directive
Calls for SUPD to clarify treatment of fossil-free plastics, align rules with decarbonisation goals, harmonise EPR and fee eco-modulation, and incentivise renewable-carbon supply chains.
17 March 2026
Kemira obtains PMRA approval in Canada for KemConnect DEX
Chlorine-free performic-acid wastewater disinfection; used in Paris 2024 wastewater works. Combines on-site generation, real-time monitoring and dosing algorithm. Canada rollout pending approvals
16 March 2026
Bilfinger earns fourth straight EcoVadis Gold with 83-point score
Ranks top 1% in industry, top 2% globally; SBTi-validated 2025 climate targets toward net-zero by 2050; EcoVadis scores: Env86, Labor79, Ethics89, Proc86; GHG -8% (S1&2), -4% (S3); LTIFR 0.18
16 March 2026
Terumo Aortic's Fenestrated TREO® Gains FDA Breakthrough Status
The FDA's Breakthrough Device Designation accelerates the review of Fenestrated TREO®, a custom stent-graft for complex abdominal aortic aneurysms, offering a tailored, minimally invasive solution.
16 March 2026
Petrobras to Acquire Full Ownership of Tartaruga Verde and Espadarte Fields
Petrobras will pay $450M to acquire Petronas' 50% stake in Tartaruga Verde and Espadarte fields, regaining full ownership. Completion awaits regulatory approval.
16 March 2026
Aptar's Nasal Delivery System in Phase II Study for SPONTAN® Spray
Aptar's nasal system aids LTR Pharma's SPONTAN® Phase II study, focusing on safety, tolerability, and pharmacokinetics for erectile dysfunction treatment.
16 March 2026
Neste Advocates Strong Anti-Fraud Measures in Biofuels Supply Chains
Neste emphasizes rigorous supplier audits, traceability, and collaboration to combat fraud in renewable raw materials, ensuring compliance and authenticity in its supply chains.
16 March 2026
Lilly's EBGLYSS Achieves Positive Phase 3 Results in Pediatric Atopic Dermatitis
EBGLYSS shows significant skin improvement and itch relief in children with moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints in Phase 3 ADorable-1 trial.
13 March 2026
MOL and Slovnaft File Complaint Against JANAF's Pricing Practices
JANAF's pricing is deemed excessive and unjustified, impacting energy supply security. MOL and Slovnaft have raised concerns with the European Commission over these practices.
13 March 2026
Petrobras Adjusts Diesel Prices
Diesel prices rise by R$ 0.38/liter for distributors. Federal tax exemptions and a subsidy program mitigate consumer impact.
13 March 2026
GSK's Arexvy RSV Vaccine Approved for Expanded Use in US Adults 18-49
FDA expands Arexvy's use to adults 18-49 at risk for severe RSV. Phase III trials show efficacy and safety. 17,000 hospitalizations annually in this age group.
13 March 2026
Petrobras Joins Diesel Subsidy Program
Petrobras' Board approves joining a diesel subsidy, pending regulatory review. The move aligns with its strategy to maintain market share and profitability without price volatility.
12 March 2026
Lhyfe Maintains Strong ESG Rating from Ethifinance
Lhyfe scored 88/100 in 2024 ESG performance, reflecting strong environmental efforts and energy independence, with improved ratings since 2022.
12 March 2026
Johnson & Johnson's TECNIS PureSee IOL Gains FDA Approval for Cataract Surgery
TECNIS PureSee IOL offers enhanced vision for cataract patients, reducing reliance on glasses and maintaining contrast sensitivity, with 97% reporting no bothersome visual disturbances.
← Previous
Next →
